Jazz Pharmaceuticals, shared on LinkedIn:
“Today, we announced positive combination survival results from the Phase 3 HERIZON-GEA-01 trial investigating our first-line treatment for adults with HER2+ advanced gastroesophageal adenocarcinoma (GEA).
Learn more
Advanced HER2+ GEA remains an aggressive cancer with a poor prognosis. These results reinforce the potential of our HER2-targeted therapy following the recent FDA approval in HER2+ advanced GEA, and highlights our continued commitment to redefining care for people living with difficult-to-treat cancers.”
You can also read: FDA Approves Ziihera With and Without Tislelizumab Plus Chemotherapy for First-Line HER2-Positive Gastroesophageal Adenocarcinoma
